Functional status to predict acute care utilization among patients receiving systemic anticancer therapy in a QMENTUM diamond cancer center: A real-world cohort study.
TL;DR
The findings support the incorporation of PS assessment into routine oncology practice to identify patients who may benefit from targeted supportive care strategies and closer monitoring, supporting proactive care delivery within high-quality oncology programs.
Abstract
92 Background: Acute care utilization (ACU), including emergency department (ED) visits, hospitalizations, and intensive care unit (ICU) admissions, is associated with increased healthcare costs, treatment interruptions, and worse patient outcomes. Identifying patients at increased risk for ACU may facilitate targeted supportive care interventions. Thus, we sought to identify clinical factors associated with ACU among patients receiving systemic anticancer therapy at a QMENTUM Diamond-accredited cancer center in Brazil. Methods: We conducted a retrospective cohort study of adult patients with solid tumors treated at a Brazilian cancer center between 2023 and 2025. The primary outcome was ACU, defined as the occurrence of at least one of the following within the follow-up period: ED visit within 30 days of treatment, hospitalization within 30 days, or ICU admission. Demographic and clinical variables included age, treatment intent, and Eastern Cooperative Oncology Group (ECOG) performance status (PS). Multivariable logistic regression was used to evaluate factors independently associated with ACU. Results: A total of 161 patients were included. The median age was 61 years (range, 25-92), with 42.9% were aged ≥65 years; 68.3% were female. The most common malignancies were breast (41.0%), gastrointestinal (23.6%), and gynecologic (6.2%) cancers. Most patients had advanced-stage disease (III-IV, 70.8%). Overall, 52 patients (32.3%) experienced ACU. ACU was more frequent among patients aged ≥65 years than among younger patients (43.5% vs. 23.9%, p=0.008), and among those receiving palliative versus curative-intent treatment (39.7% vs. 25.3%; p=0.06). A stepwise increase in ACU was observed with worsening PS, occurring in 14 of 76 patients (18.4%) with ECOG 0, 18 of 56 (32.1%) with ECOG 1, and 20 of 29 (69.0%) with ECOG ≥2 (p<0.001). In multivariable analysis adjusting for age and treatment intent, ECOG ≥2 remained independently associated with ACU (OR, 5.38; 95% CI, 2.07-13.97; p=0.001). Neither age ≥65 years (OR, 1.44; 95% CI, 0.67-3.09; p=0.35) nor palliative treatment intent (OR, 1.41; 95% CI, 0.68-2.93; p=0.35) was independently associated with ACU. Conclusions: In this real-world Brazilian cohort, ECOG PS was the strongest predictor of ACU. While older age and palliative treatment intent were associated with higher rates of acute care utilization in unadjusted analyses, only ECOG ≥2 remained independently associated with risk after adjustment. These findings support the incorporation of PS assessment into routine oncology practice to identify patients who may benefit from targeted supportive care strategies and closer monitoring, supporting proactive care delivery within high-quality oncology programs.